The Plasmid DNA Manufacturing is Fastest Growing Segment Fueling the Growth of Plasmid DNA Manufacturing Market

Plasmid DNA Manufacturing Market

 The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Plasmid DNA is circular double stranded DNA molecules capable of autonomous replication distinct from chromosomal DNA. They are important tools in genetic engineering, gene therapy, transgenic technology and other basic research as they can be modified, amplified and transferred between organisms. Plasmid DNA manufacturing plays an important role in production of DNA/RNA based vaccines, gene therapies and other advanced therapies.

Market key trends:

Increasing investment in gene therapy and DNA based vaccine manufacturing is expected to drive the plasmid DNA manufacturing market growth over the forecast period. For instance, according to Alliance for Regenerative Medicine 2020 report, global investment in cell and gene therapy increased by 50% in 2020, reaching $24.9 billion. Further, ongoing clinical research for infectious diseases and cancer is also fueling the demand for high quality and regulatory compliant plasmid DNA production. Growing need for advanced and cost effective manufacturing methods like continuous processing is further expected to boost the plasmid DNA manufacturing market.

Segment Analysis

The global plasmid DNA manufacturing market is segmented into vector type, application, end user and region. Based on vector type, the market is divided into bacterial plasmid vectors and non-bacterial plasmid vectors. The bacterial plasmid vectors segment dominates the market as they are inexpensive and easy to produce when compared to non-bacterial plasmid vectors. By application, the market is categorized into gene and cell therapy, DNA vaccines, cancer therapy, and others. The gene and cell therapy segment holds the largest market share owing to the increasing R&D in gene therapies for treating genetic disorders. On the basis of end user, the market is bifurcated into biopharmaceutical companies, research organizations, and contract manufacturing organizations. Biopharmaceutical companies dominate the market due to high adoption of plasmid DNA for manufacturing therapies and vaccines.

Key Takeaways

The global plasmid DNA manufacturing market is expected to witness high growth, exhibiting a CAGR of 22% over the forecast period, due to increasing R&D investments for cell and gene therapies.

Regional analysis - North America dominates the global plasmid DNA manufacturing market, followed by Europe. This is attributed to presence of major players and growing expenditures on gene and cell therapy research in the U.S. and Canada. Additionally, Asia Pacific is anticipated to witness the fastest growth over the forecast period due to increasing government funding for gene therapies research in countries such as China and India.

Key players - Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.

Read More

https://www.dailyprbulletin.com/plasmid-dna-manufacturing-market-size-share-growth-outlook-2023/